1Larsen PR, Davies TF, Hay LD. The thyroid gland. In:Wilson JD, Foster DW, Kronenberg HM, et al. Williams Textbook of Endocrinology[ M ]. 9th ed. Beijing: Science Press, 2000. 389 -515.
2Noth D, Gebauer M, Muller B,et al. Graves' ophthalmopathy:natural history and treatment outcomes[J]. Swiss Med Wkly,2001,20:131.
3Clauser L, Galie M, Sarti E,et al. Rationale of treatment in Graves ophthalmopathy [ J ]. Plast Reconstr Surg, 2001,108 (7):1880- 1894.
4Heufelder AE. Interactions of fibroblasts, adipocytes and immunocompeent cells in the pathogenesis of endocrine ophthalmopathy[J]. Acta Med Austriaca,2001,28(4) :89 - 92.
5Epishin AV, Epishina NA, Solomko LD,et al. Immunologically active preparations in the complex treatment of patients with diffuse toxic goiter[J]. Klin Med (Mossk), 1988,66(2): 102-106.
3Mounts M,Pmnmel M,Wiersinga W,et a1.Clinical activity score asaguide in the management of patients with Graves ophthalmo-pathy[J].Clin Endocrinol,2007,47(1):9-14.
4Hsieh MH,Chen CC,Wang TY et al.Chylous ascites as a manifestation of thyrotoxic cardiomyopathy in a patient with untreated Graves'disease.[J].Thyroid,2010,20(6):653-655.
